Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease

被引:89
|
作者
Xu, PY
Liang, R
Jankovic, J
Hunter, C
Zeng, YX
Ashizawa, T
Lai, D
Le, WD
机构
[1] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Cellular & Mol Biol, Houston, TX 77030 USA
[3] Univ Texas, Sch Publ Hlth, Dept Biometry, Houston, TX USA
[4] MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX USA
[5] Sun Yat Sen Univ Med Sci, Dept Neurol, Guangzhou, Peoples R China
关键词
D O I
10.1212/WNL.58.6.881
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To determine whether the Nurr1 gene, which is critical for the development and maintenance of nigral dopaminergic neurons, is a risk factor associated with PD. Background: The Nurrl gene is highly expressed in the dopaminergic neurons in the midbrain. Knockout of the gene results in agenesis of nigral dopaminergic neurons and heterozygous knockout mice increases 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. Methods: This study included 105 patients with familial PD (fPD) and 120 patients with sporadic PD (sPD) and 221 age-matched healthy control subjects. The polymorphisms and mutations of the Nurr1 gene in patients with PD were initially examined by heteroduplex analysis and sequencing analysis from PCR-amplified Nurr1 gene fragments. A polymorphism in the BseRI restriction site was identified, and a relatively large-scale analysis then was conducted by three independent investigators who were blinded to the clinical status of the subjects. Results: A homozygous 7048G7049 polymorphism was found in intron 6 of the Nurr1 gene, which was significantly higher in fPD (10/105; 9.5%) and in sPD (5/120; 4.2%) compared with healthy control subjects (2/221; 0.9%). The mean age and the SD at onset of these homozygote patients with PD was 52 +/- 15 years for fPD and 46 7 years for sPD. The clinical features of these homozygote patients with PD did not differ from those of typical PD. Conclusions: The homozygote polymorphism of 7048G7049 in intron 6 of the Nurr1 gene is associated with typical PD.
引用
收藏
页码:881 / 884
页数:4
相关论文
共 50 条
  • [31] NURR1 promoter polymorphisms:: Parkinson's disease, schizophrenia, and personality traits
    Carmine, A
    Buervenich, S
    Galter, D
    Jönsson, EG
    Sedvall, GC
    Farde, L
    Gustavsson, JP
    Bergman, H
    Chowdari, KV
    Nimgaonkar, VL
    Anvret, M
    Sydow, O
    Olson, L
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2003, 120B (01): : 51 - 57
  • [32] Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease
    Wang, Jun
    Bi, Weina
    Zhao, Wei
    Varghese, Merina
    Koch, Rick J.
    Walker, Ruth H.
    Chandraratna, Roshantha A.
    Sanders, Martin E.
    Janesick, Amanda
    Blumberg, Bruce
    Ward, Libby
    Ho, Lap
    Pasinetti, Giulio M.
    ONCOTARGET, 2016, 7 (07) : 7469 - 7479
  • [33] Decreased Nurr1 mRNA in peripheral blood lymphocytes in Parkinson's disease
    Pan, TH
    Xie, WJ
    Jankovic, J
    Le, WD
    NEUROLOGY, 2004, 62 (07) : A108 - A108
  • [34] Nurr1 downregulation is caused by CREB inactivation in a Parkinson's disease mouse model
    Xu, Xiaoyi
    He, Xin
    Ma, Shanshan
    Li, Mingtao
    Huang, Qiaoying
    NEUROSCIENCE LETTERS, 2021, 759
  • [35] Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease
    Oh, Sang-Min
    Chang, Mi-Yoon
    Song, Jae-Jin
    Rhee, Yong-Hee
    Joe, Eun-Hye
    Lee, Hyun-Seob
    Yi, Sang-Hoon
    Lee, Sang-Hun
    EMBO MOLECULAR MEDICINE, 2015, 7 (05) : 510 - 525
  • [36] Proteasomal Inhibition as a Treatment Strategy for Parkinson's Disease: The Impact of α-Synuclein on Nurr1
    Devine, Michael J.
    JOURNAL OF NEUROSCIENCE, 2012, 32 (46): : 16071 - 16073
  • [37] Off-target implications of Nurr1 agonist therapy in Parkinson's disease
    Steece-Collier, K.
    Collier, T.
    Stancati, J.
    Kemp, C.
    Daley, B.
    Sortwell, C.
    MOVEMENT DISORDERS, 2017, 32
  • [38] An optimized Nurr1 agonist provides disease-modifying effects in Parkinson’s disease models
    Woori Kim
    Mohit Tripathi
    Chunhyung Kim
    Satyapavan Vardhineni
    Young Cha
    Shamseer Kulangara Kandi
    Melissa Feitosa
    Rohit Kholiya
    Eric Sah
    Anuj Thakur
    Yehan Kim
    Sanghyeok Ko
    Kaiya Bhatia
    Sunny Manohar
    Young-Bin Kong
    Gagandeep Sindhu
    Yoon-Seong Kim
    Bruce Cohen
    Diwan S. Rawat
    Kwang-Soo Kim
    Nature Communications, 14
  • [39] An optimized Nurr1 agonist provides disease-modifying effects in Parkinson's disease models
    Kim, Woori
    Tripathi, Mohit
    Kim, Chunhyung
    Vardhineni, Satyapavan
    Cha, Young
    Kandi, Shamseer Kulangara
    Feitosa, Melissa
    Kholiya, Rohit
    Sah, Eric
    Thakur, Anuj
    Kim, Yehan
    Ko, Sanghyeok
    Bhatia, Kaiya
    Manohar, Sunny
    Kong, Young-Bin
    Sindhu, Gagandeep
    Kim, Yoon-Seong
    Cohen, Bruce
    Rawat, Diwan S. S.
    Kim, Kwang-Soo
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [40] TRANSCRIPTION FACTOR NURR1 IN DOPAMINE NEURON DEVELOPMENT AND NEURODEGENERATION ASSOCIATED WITH PARKINSON'S DISEASE
    Le, W.
    PARKINSONISM & RELATED DISORDERS, 2020, 79 : E28 - E28